The role of oligoclonal band count and IgG index in treatment response and disease activity in multiple sclerosis.

Biomarker Disease activity Immunoglobulin IgG index Multiple sclerosis Oligoclonal band number Treatment

Journal

Multiple sclerosis and related disorders
ISSN: 2211-0356
Titre abrégé: Mult Scler Relat Disord
Pays: Netherlands
ID NLM: 101580247

Informations de publication

Date de publication:
27 Jan 2024
Historique:
received: 25 10 2023
revised: 04 12 2023
accepted: 17 12 2023
medline: 10 2 2024
pubmed: 10 2 2024
entrez: 9 2 2024
Statut: aheadofprint

Résumé

Multiple sclerosis (MS) is an inflammatory demyelinating central nervous system (CNS) disease. Among the paraclinical tests, brain and spinal Magnetic Resonance Imaging (MRI) is primarily involved in the diagnosis process, and cerebrospinal fluid (CSF) analysis is fundamental in diagnosing MS and the differential diagnosis. A positive relationship was demonstrated between oligoclonal band (OCB) positivity, CSF band number and immunoglobulin G(IgG) index. The study aimed to evaluate whether the number of OCB can predict disease activity and determine a correlation with the IgG index. Our study included 401 MS patients who had relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), clinic isolated syndrome (CIS), radiologic isolated syndrome (RIS), Neuromyelitis optica spectrum disorder (NMOSD) and Acute disseminated encephalomyelitis (ADEM) with OCB number groups of 2-4, 4-8, 8-12, and 12 and above. No significant correlation was observed between IgG index, pre-and post-treatment EDSS (Expanded Disability Status Scale Scores) and disease-modifying therapies (DMT). Drug response was better in the patient group with band number between 2 and 8 and post-treatment EDSS scores were lower (1.62±0.44). The study results suggested that band number may be as valuable as the IgG index and a predictive biomarker for disease activity.

Sections du résumé

BACKGROUND/AIM OBJECTIVE
Multiple sclerosis (MS) is an inflammatory demyelinating central nervous system (CNS) disease. Among the paraclinical tests, brain and spinal Magnetic Resonance Imaging (MRI) is primarily involved in the diagnosis process, and cerebrospinal fluid (CSF) analysis is fundamental in diagnosing MS and the differential diagnosis. A positive relationship was demonstrated between oligoclonal band (OCB) positivity, CSF band number and immunoglobulin G(IgG) index. The study aimed to evaluate whether the number of OCB can predict disease activity and determine a correlation with the IgG index.
METHODS METHODS
Our study included 401 MS patients who had relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), clinic isolated syndrome (CIS), radiologic isolated syndrome (RIS), Neuromyelitis optica spectrum disorder (NMOSD) and Acute disseminated encephalomyelitis (ADEM) with OCB number groups of 2-4, 4-8, 8-12, and 12 and above.
RESULTS RESULTS
No significant correlation was observed between IgG index, pre-and post-treatment EDSS (Expanded Disability Status Scale Scores) and disease-modifying therapies (DMT). Drug response was better in the patient group with band number between 2 and 8 and post-treatment EDSS scores were lower (1.62±0.44).
CONCLUSION CONCLUSIONS
The study results suggested that band number may be as valuable as the IgG index and a predictive biomarker for disease activity.

Identifiants

pubmed: 38335838
pii: S2211-0348(23)00890-8
doi: 10.1016/j.msard.2023.105391
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

105391

Informations de copyright

Copyright © 2023. Published by Elsevier B.V.

Déclaration de conflit d'intérêts

Declaration of competing interest None.

Auteurs

Esra Taşkıran (E)

Antalya Training and Research Hospital Neurology Clinic, Turkey, Esra Taşkıran. Electronic address: es_ranil@hotmail.com.

Murat Terzi (M)

Ondokuz Mayıs University Faculty of Medicine, Department of Neurology, Turkey, Murat Terzi.

Elif Merve Helvacı (EM)

Ondokuz Mayıs University Graduate School of Education, Department of Neurosciences, Turkey, Elif Merve Helvacı.

Meltem Zeycan Eser (MZ)

Ondokuz Mayıs University, Department of Biochemistry, Turkey, Meltem Zeycan ESER.

Bahattin Avcı (B)

Ondokuz Mayıs University, Department of Biochemistry, Turkey, Bahaddin Avcı.

Turan Ömer Faruk (T)

Uludag University Faculty of Medicine, Department of Neurology, Turkey, Ömer Faruk Turan.

Mehmet Fatih Yetkin (MF)

Erciyes University Faculty of Medicine, Turkey, Mehmet Fatih Yetkin.

Vedat Çilingir (V)

Van Yüzüncüyıl University Faculty of Medicine, Turkey, Vedat Çilingir.

Levent Sinan Bir (LS)

Pamukkale University Faculty of Medicine, Turkey, Levent Sinan Bir.

Sibel Canbaz Kabay (SC)

Dokuz Eylul University Faculty of Medicine, Turkey, Sibel Canbaz Kabay.

Nuray Bilge (N)

Atatürk University Faculty of Medicine, Turkey, Nuray Bilge.

Turan Poyraz (T)

Private Medifema Hospital, Turkey, Turan Poyraz.

Caner Feyzi Demir (CF)

Firat University Faculty of Medicine, Turkey, Caner Feyzi Demir.

Dilcan Kotan Dündar (DK)

Sakarya University Faculty of Medicine, Turkey, Dilcan Kotan Dündar.

Özgül Ocak (Ö)

Muğla University Faculty of Medicine, Turkey, Ozgul Ocak.

Mustafa Çam (M)

Çanakkale University Faculty of Medicine, Turkey, Mustafa Çam.

Hatice Mavioğlu (H)

Celal Bayar University Faculty of Medicine, Turkey, Hatice Mavioğlu.

Yaşar Altun (Y)

Adıyaman University Faculty of Medicine, Turkey, Yaşar Altun.

Adnan Karaibrahimoğlu (A)

Süleyman Demirel University Faculty of Medicine, Department of Biostatistics and Medical Informatics, Turkey, Adnan Karaibrahimoğlu.

Classifications MeSH